buyWeak
GILEAD SCIENCES, INC. bought $1.8M of XLO
owner at Xilio Therapeutics, Inc.. 1,759,978 shares at an average of $1.04, traded Dec 18, 2024, filed Dec 19, 2024.
Conviction score
38Value
$1.8M
1,759,978 shares
Holdings after
9,105,451
+24% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-24-020910, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | POpen-market purchase Common Stock | +1,759,978 | $1.04 | $1.8M | 9,105,451 | Dec 19, 2024 |
| Dec 18, 2024 | POpen-market purchase Prefunded Warrants (right to buy)derivative | +6,092,816 | $1.04 | $6.3M | 9,975,266 | Dec 19, 2024 |
Related signals
Other insiders at Xilio Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 0Weak | sell 210b5-1 | XLO Xilio Therapeutics, Inc. | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | $1,774 | 1,803 | |
| 5Weak | sell 210b5-1 | XLO Xilio Therapeutics, Inc. | Frankenfield Christopher James Chief Financial Officer | $6,841 | 6,954 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.